The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases.
 
Takehiro Tozuka
No Relationships to Disclose
 
Satoru Kitazono
Honoraria - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
 
Hiroaki Sakamoto
No Relationships to Disclose
 
Hiroshi Yoshida
No Relationships to Disclose
 
Yoshiaki Amino
No Relationships to Disclose
 
Shinya Uematsu
No Relationships to Disclose
 
Takahiro Yoshizawa
No Relationships to Disclose
 
Tsukasa Hasegawa
No Relationships to Disclose
 
Ryo Ariyasu
No Relationships to Disclose
 
Ken Uchibori
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
 
Noriko Yanagitani
Honoraria - Bayer Yakuhin; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
 
Takeshi Horai
No Relationships to Disclose
 
Makoto Nishio
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AbbVie; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Teijin Pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)